ORAL SEMAGLUTIDE FOR WEIGHT LOSS

Oral Semaglutide is a medication that has been developed to assist individuals in their weight loss journey. It belongs to a class of drugs called GLP-1 receptor agonists, which have shown promising results in helping people achieve and maintain a healthier weight. Although customarily administered as a once weekly injection, oral daily options make the medication available to those who are unable or unwilling to take an injection. Oral Semaglutide is the active ingredient found in the popular Novo Nordisk medication Rybelsus©.

CRITERIA FOR PATIENT ELIGIBILITY

  BMI Criteria

We consider individuals with a BMI of 27 or higher for Semaglutide as part of our weight management program.

Medical History and Comorbidities

Our healthcare providers carefully review each patient's medical history, including existing health conditions, to ensure safety and efficacy.

  Weight-Related Health Issues

Semaglutide is recommended for patients with at least one weight-related health issue, such as type 2 diabetes, hypertension, or  dyslipidemia.

  Lifestyle Factors

Patient eligibility also takes into account lifestyle factors, including a commitment to dietary changes and increased physical activity.

OUR PATIENT EVALUATION PROCESS

Consultation with our Providers

Patients interested in Oral Semaglutide undergo a comprehensive consultation with our experienced board-certified physicians.

Medical Tests and Assessments

Additional tests or assessments may be conducted to further evaluate overall health and identify potential contraindications.

Discussion of Treatment Goals

We engage in open discussions with patients to understand their weight management goals and expectations, ensuring a collaborative approach.

Informed Decision-Making:

We prioritize patient education, providing detailed information about the benefits, risks, and expected outcomes of Semaglutide to facilitate informed decision-making.

PARTNERING WITH COMPASSIONATE HEALTHCARE

Our mission is to support our patients on their weight management journey. If you are considering oral or injectable Semaglutide, we invite you to consult with our healthcare providers. Together, we can tailor a personalized treatment plan to help you achieve your weight loss goals.

Understanding the Benefits of Oral Semaglutide for Weight Loss

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising results in aiding weight loss. Here are some key benefits:

Appetite Reduction

Oral semaglutide helps reduce appetite and caloric intake, leading to significant weight loss in many patients. This can help you feel more satisfied with smaller portions, making it easier to maintain a calorie deficit. This can be particularly beneficial for individuals with type 2 diabetes who are overweight or obese.

Improved Blood Sugar Control

Originally developed for diabetes management, oral semaglutide not only helps regulate blood sugar but also contributes to weight loss. By optimizing insulin levels, it promotes better utilization of glucose and fat for energy. Effective blood sugar control and weight loss can lead to a reduction in diabetes-related symptoms, such as fatigue, excessive thirst, and frequent urination.

Enhanced Insulin Sensitivity

Oral Semaglutide may improve insulin sensitivity, making your body more efficient in utilizing insulin and reducing the amount of insulin required to control blood glucose levels and thereby decreasing the burden on pancreatic beta cells.

Sustainable Weight Loss

Studies have shown that individuals taking oral semaglutide for weight loss experienced significant and sustained reductions in body weight. This makes it a potential long-term solution for managing obesity.

Body Mass Index (BMI) is the measure of health and fitness endorsed by the Surgeon General of the United States. It takes into consideration the height and weight of a person to give an accurate index of what his/her weight should be. A
BMI of up to 25 is considered healthy.

Any number between 25 – 29 means the person is overweight. A reading between 30 – 39 is an indication of obesity, placing the individual at high risk of developing heart disease, high blood pressure, diabetes, and other ailments. A reading of 40+ is an indication of extreme obesity, placing a person at highest risk of health problems.

Understanding your BMI provides valuable insights into your weight-related health. However, it is crucial to interpret this information within the broader context of your  individual health profile. For a comprehensive assessment and tailored guidance, consult with your healthcare provider.

Your Path to Affordable and Effective Weight Loss

86.4%

Of participants using GLP-1 medication Wegovy® achieved significant wight loss, compared to only 31.5% in the placebo group.

14.9%

Body weight loss on average among patients in the study group using GLP-1 medicine, Wegovy©)

37.8%

Reduction in high-sensitivity C-reactive protein level in patients using Wegovy®, compared to placebo.

20%

Reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 20%

*STEP 1 Trial in participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention. Data available at NEJM: Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine
*SELECT Trial in patients with preexisting cardiovascular disease and overweight or obesity but without diabetes. Data available at NEJM: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine

Ready to transform your body and start living your best life?

Our weight loss program can help you achieve your goals with expert guidance, prescription medication, and real results. Don't wait another day to start the change you want – join us today and take the first step towards a healthier, happier you!

ORAL SEMAGLUTIDE PROGRAM

  • Telehealth or office evaluation to determine candidacy for treatment

  • All your questions answered by our support staff

  • Pay one low monthly price – no need to worry about deductibles or copays

  • Pay as you go – No Contracts or Autopay

Frequently Asked Questions

Oral Semaglutide, the active ingredient in RYBELSUS®, is a medication that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. It works by influencing appetite control centers in the brain and regulating blood sugar levels. This dual action promotes weight loss by reducing calorie intake and improving metabolic function.

Oral Semaglutide is generally prescribed for individuals with a body mass index (BMI) of 27 or higher who have at least one weight related health issue (such as diabetes, high blood pressure, or high cholesterol). However, eligibility is determined on a case-by-case basis by healthcare professionals. Oral formulations of semaglutide are taken daily compared to injectable versions of the medication. Oral routes are best for patients who have a fear of needles and weekly injections.

Oral doses of semaglutide are usually sublingual and dissolve under the tongue. They are taken once per day.

Individuals typically start experiencing weight loss within the first few weeks of the program, with continued progress over time. Consistency in medication use, coupled with a healthy lifestyle, contributes to optimal results.

Your healthcare provider will determine the most suitable approach based on your individual needs. Semaglutide can be used alongside dietary changes and increased physical activity for a comprehensive weight loss plan.

Common side effects may include nausea, vomiting, or abdominal pain, which often improve over time and are usually mild and transient. Serious side effects are rare but may include allergic reactions or pancreatitis. Titrating of Semaglutide slowly, is the best way for the body to adapt and avoid side effects. If you experience persistent or severe side effects, consult your healthcare provider promptly.

Compounded medications are customized treatments prepared in a state Board of Pharmacy licensed compounding facility, based on a prescription from a licensed healthcare professional.

Compounded medications do not receive pre-market approval from the FDA because they are not mass-produced for the general public. Instead, they are created specifically for individual patients as prescribed by a healthcare provider. As a result, the dosage, method of administration, and effectiveness may vary from commercially available products.